PFIZER Aktie

 

Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before you chase the bigger payout, the coverage numbers behind each dividend tell a very different story....

How The NYT Hid Big Pharma PR Titan Jack Leslie In Plain Sight Authored by Paul D. Thacker via The DisInformation Chronicle, New York Times reporter Sheryl Gay Stolberg wrote one of the most hilarious, misleading pieces I've seen in recent months, castigating the NIH for a new vaccine injury clinic based on a leaked statement by Jack Leslie, a senior advisor to the PR firm Weber Shandwick which represents most major vaccine manufacturers. I'm not joking. This is the journalism I get for my paid subscription to the New York Times. Like most senior executives at the global PR firm Weber Shandwick, Jack Leslie makes buckets of money helping corporations sell themselves and their products to the American public. In the last handful of years, Weber Shandwick's clients have included the bulk of the global vaccine giants including Pfizer, Moderna, GSK, Sanofi, Novartis, and Eli Lilly. But when he's not raking in oodles of cash repping corporate America, Leslie also takes on some unpaid healthcare...

JD HEALTH (06618.HK) has entered into a strategic partnership with Pfizer. The two parties will jointly explore a patient-centric and technology-driven integrated pharmaceutical and healthcare service model across disease areas including obesity, diabetes, respiratory and anti-infective diseases, dermatological diseases, migrain......

In the latest trading session, Pfizer (PFE) closed at $30.11, marking a +2.28% move from the previous day....

Moderna's (NASDAQ:MRNA) push into cancer treatment is drawing heavy buying as a closely followed melanoma presentation approaches. Shares of Moderna are up 7% to $241.89 during the trading session, running ahead of larger drugmakers and the healthcare sector fund. Meanwhile, Bristol Myers Squibb (NYSE:BMY) stock is up 5% to $61.55. Pfizer (NYSE:PFE) stock is up […]...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

RALEIGH, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Slate Medicines, Inc. (“Slate”), a clinical-stage biotechnology company committed to advancing innovative new therapies that may broaden the treatment paradigm and potentially improve outcomes for people with migraine and other headache disorders, today announced the appointment of Stephen K. Brannan, MD, and John D. Young to the company's Board of Directors. Dr. Brannan brings more than 25 years of clinical development experience in CNS disorders and most recently served as the Chief Medical Officer of Karuna Therapeutics. Mr. Young brings more than 35 years of biopharmaceutical industry experience, including serving as a member of the Executive Leadership Team at Pfizer, most recently as Group President and Chief Business Officer....

The stock has outperformed the market this year, and it still looks heavily undervalued....

Mr. Germano brings more than 35 years of biopharmaceutical leadership experience, including as Group President of Pfizer's Global Innovative Pharmaceutical business Extensive public company board experience, including current service as Chairman of Entera Bio and as a director of......

Pfizer's Q3 results will shed light on its non-oncology portfolio, as demand trends, pricing pressure and vaccine sales shape performance across key therapies....

Pfizer's 5.8% yield looks tempting until you check what the dividend is actually costing the company relative to its cash generation. The math behind that payout is more uncomfortable than the headline numbers suggest....

Pfizer's dividend yield is attractive, but investors need to know if it can maintain it....

Vaccine stocks are cracking under intense selling pressure, and one small developer with no control over its own commercial fate is bearing the worst of it. Whether its big-pharma partner can change that story is the question every shareholder now faces....

Profit taking is hitting one of biotech's hottest trades, and the selling is landing heaviest on the stock that ran the furthest. Moderna (NASDAQ:MRNA) stock is down 10% to $214.03 in morning trading, giving back part of a steep run tied to its personalized cancer vaccine. Meanwhile, BioNTech SE (NASDAQ:BNTX) stock is down 2% to […]...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Verizon and Pfizer pay generous dividends, and each has a different path to growth. Here's how income investors can lock in yield before year-end....

Healthcare is drawing fresh buying as money moves away from the market's popular technology trade, and one messenger RNA (mRNA) name is pulling well ahead of the pack. Moderna (NASDAQ:MRNA) shares are up 6% to $239.74 in afternoon trading, a gain that dwarfs the rest of the peer group. That advance arrives without a new […]...

AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readouts expected over the next year....

The latest trading day saw Pfizer (PFE) settling at $29.21, representing a +2.96% change from its previous close....

Senior appointments from Pfizer, Novartis, Arbor Biotechnologies, and Orum Therapeutics bring preclinical development, structural biology, and portfolio strategy depth as MindWalk prepares its programs for preclinical efficacy studiesBOSTON--(BUSINESS WIRE)--$HYFT #ai--MindWalk Holdings Corp. (NASDAQ: HYFT) (“MindWalk” or the “Company”), a Bio-Native AI company, today announced three senior appointments that strengthen its Boston-based development leadership as the Company's pipeline advances toward preclinical efficacy studies. Zachary Maben, PhD, joins as Director, Antigen Discovery & Protein Engineering, from Arbor Biotechnologies and previously Pfizer. Joanne Lim, PhD, joins as Director, Preclinical Development, from Orum Therapeutics and previously Codiak Biosciences and Novartis. Shuji Sato, PhD, Vice President, Innovative Solutions, a MindWalk veteran with prior roles at Pfizer and Dragonfly Therapeutics, expands his responsibilities to include the Company's pipeline. Preclinical efficacy...